KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been assigned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $29.1667.

KALV has been the subject of several analyst reports. Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Needham & Company LLC lifted their price objective on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Citizens Jmp dropped their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Finally, TD Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd.

KalVista Pharmaceuticals Trading Down 1.4%

KalVista Pharmaceuticals stock opened at $14.91 on Tuesday. The company has a market cap of $753.70 million, a price-to-earnings ratio of -3.77 and a beta of -0.19. The firm has a 50-day moving average of $15.63 and a 200-day moving average of $13.82. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. KalVista Pharmaceuticals has a one year low of $9.23 and a one year high of $19.00.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 3,354 shares of the company’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $15.70, for a total value of $52,657.80. Following the transaction, the chief executive officer directly owned 428,286 shares in the company, valued at $6,724,090.20. The trade was a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Brian Piekos sold 4,471 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $60,134.95. Following the sale, the chief financial officer owned 10,529 shares of the company’s stock, valued at approximately $141,615.05. This represents a 29.81% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 31,355 shares of company stock worth $451,591. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in KalVista Pharmaceuticals by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock valued at $30,464,000 after purchasing an additional 88,720 shares during the period. Tudor Investment Corp ET AL acquired a new stake in shares of KalVista Pharmaceuticals during the third quarter worth $24,360,000. State Street Corp boosted its position in shares of KalVista Pharmaceuticals by 21.3% in the fourth quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock valued at $30,874,000 after acquiring an additional 336,195 shares during the period. Parkman Healthcare Partners LLC grew its stake in shares of KalVista Pharmaceuticals by 155.5% in the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after acquiring an additional 1,055,940 shares in the last quarter. Finally, Emerald Advisers LLC increased its position in KalVista Pharmaceuticals by 30.2% during the third quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock worth $16,458,000 after acquiring an additional 313,205 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.